Clinical Trials

198 enrolled

Colorectal Neoplasms

NCT04201561 2023-06-26

SELENIUM

68 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peripheral Nervous System Diseases

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

228 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05104281 2023-03-29

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

60 enrolled

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT02633189 2023-03-24

BEVERLY

200 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT02761070 2023-03-08

RE-GEND

146 enrolled

CNS

Glioblastoma, Recurrence, Disease Progression

NCT05648071 2022-12-13

SPBPDC

60 enrolled

Advanced Non-squamous Non-Small-Cell Lung Cancer

NCT02743923 2021-12-21

Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer

203 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04188145 2021-10-28

BEVAMAINT

400 enrolled

Colorectal Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

427 enrolled

Ovarian Neoplasms

NCT03912415 2020-09-18

FERMATA

316 enrolled

Uterine Cervical Neoplasms

NCT04525326 2020-08-25

Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases

584 enrolled

Colorectal Neoplasms

NCT02339116 2020-02-05

TRIBE2

654 enrolled

Colorectal Neoplasms

NCT03792074 2019-01-03

To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

560 enrolled

Non-squamous Cell Non-small Cell Lung Cancer

NCT03533127 2018-07-10

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

648 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03303495 2017-10-06

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

280 enrolled

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT00408408 2017-09-18

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

1,206 enrolled 19 charts

Breast

Breast Neoplasms

NCT00433927 2014-03-14

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

568 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT00262067 2013-12-13

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

1,237 enrolled 14 charts

Breast

Breast Neoplasms

NCT00442637 2013-12-12

CAIRO3

635 enrolled

Colorectal Neoplasms

NCT01249638 2011-03-14

Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC

516 enrolled

Colorectal Cancer Metastatic

NCT00337389 2007-11-19

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

1,200 enrolled